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Convulsant Doses of a Dopamine D1 Receptor Agonist
Result in Erk-Dependent Increases in Zif268 and Arc/
Arg3.1 Expression in Mouse Dentate Gyrus
Giuseppe Gangarossa1., Manuela Di Benedetto1.¤a, Gerard J. O’Sullivan2, Mark Dunleavy3, Cristina
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Abstract
Activation of dopamine D1 receptors (D1Rs) has been shown to induce epileptiform activity. We studied the molecular
changes occurring in the hippocampus in response to the administration of the D1-type receptor agonist, SKF 81297. SKF
81297 at 2.5 and 5.0 mg/kg induced behavioural seizures. Electrophysiological recordings in the dentate gyrus revealed the
presence of epileptiform discharges peaking at 30–45 min post-injection and declining by 60 min. Seizures were prevented
by the D1-type receptor antagonist, SCH 23390, or the cannabinoid CB1 receptor agonist, CP 55,940. The effect of SKF 81297
was accompanied by increased phosphorylation of the extracellular signal-regulated protein kinases 1 and 2 (ERK), in the
granule cells of the dentate gyrus. This effect was also observed in response to administration of other D1-type receptor
agonists, such as SKF83822 and SKF83959. In addition, SKF 81297 increased the phosphorylation of the ribosomal protein S6
and histone H3, two downstream targets of ERK. These effects were prevented by genetic inactivation of D1Rs, or by
pharmacological inhibition of ERK. SKF 81297 was also able to enhance the levels of Zif268 and Arc/Arg3.1, two immediate
early genes involved in transcriptional regulation and synaptic plasticity. These changes may be involved in forms of
activity-dependent plasticity linked to the manifestation of seizures and to the ability of dopamine to affect learning and
memory.
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Introduction
Epileptic seizures are transient events due to abnormal or
synchronous electrical activity in the brain. They are widely
conceptualised to result from an imbalance between excitatory and
inhibitory neurotransmission that affects various cerebral regions,
such as the cerebral cortex, amygdala, thalamus and hippocampus.
Among various models of prolonged seizures, those based on use of
the cholinergic agonist pilocarpine or glutamate agonist kainic acid
(KA) are well characterized; both induce epileptiform events that
can develop into continuous seizures (status epilepticus; SE), leading
to neuronal cell damage, particularly within the hippocampus
[1,2,3]. In contrast, brief evoked or spontaneous seizures do not
necessarily cause permanent cell loss [4]. The generation of
epileptiform events can also be influenced by other neurotransmitter
systems that enhance or decrease the threshold for seizure
susceptibility. For instance, the endocannabinoid (eCB) system
inhibits KA-induced seizures and promotes protective mechanisms
through the activation of CB1 receptors in the hippocampus [5,6].
Earlier studies indicate that dopamine lowers seizure threshold
via activation of dopamine D1-type receptors, which include D1
(D1R) and D5 (D5R) receptors [7]. More recent evidence suggests
that the ability of dopamine to induce seizures depends on
activation of D1Rs coupled positively to cAMP signaling. Thus,
seizures induced by administration of SKF 83822, a D1-type
receptor agonist that selectively stimulates cAMP production, are
blocked by deletion of D1Rs, but not of D5Rs, while SKF 83959, a
D1-type receptor agonist that selectively stimulates phosphoinosi-
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tide hydrolysis, fails to induce seizures [8]. Furthermore, SKF
83822-induced seizures are reduced by deletion of the dopamine-
and cAMP-regulated phosphoprotein-32 kDa (DARPP-32) [9], a
critical component of the cAMP signaling machinery implicated in
D1R-mediated transmission [10]. However, the neural substrate(s)
implicated in dopamine-induced seizures and the biochemical
events associated with this phenomenon are still poorly understood.
In this study, we examined the ability of SKF 81297, a
conventional D1-type receptor agonist, to generate epileptiform
activity and affect signal transduction in the hippocampus. Our
results indicate that systemic administration of SKF 81297 evokes
acute seizures, which do not develop into SE or cause neuronal cell
death, and that this effect is associated with a rapid and transient
activation of the extracellular signal-regulated protein kinases 1
and 2 (ERK) pathway, specifically in the dentate gyrus (DG). By
controlling nuclear and cytoplasmic downstream targets as well as
a specific pattern of immediate early gene expression, the
activation of the ERK pathway may promote some forms of
activity-dependent plasticity in the dentate gyrus related to
activation of D1Rs.
Materials and Methods
Mice
Male C57BL/6 mice were obtained at 8 weeks from Taconic
(Tornbjerg, Denmark) and Harlan (Bicester, UK). Mutant mice
with deletion of the Drd1a gene on an F2 hybrid (1296C57BL/6J)
background were generated as described previously (Drago et al.,
1994) and backcrossed to wildtype C57BL/6J for 5 generations.
Analysis of isolated genomic DNA by PCR was used to genotype
the progeny of heterozygous D1R mutant intermatings. Animals
were housed in groups of five under standardized conditions with a
12 h light/dark cycle, stable temperature (20uC), and controlled
humidity (40–50%). All studies were performed in accordance
with the European Communities Council Directive 86/609/EEC
for the care and use of experimental animals. These studies were
approved by the Research Ethics Committee of Karolinska
Institutet and the Royal College of Surgeons in Ireland. They
were conducted under licence from the Swedish Animal Welfare
Agency and the Department of Health & Children, Ireland, in
accordance with the European Communities Council Directive
86/609/EEC for the care and use of experimental animals.
Drugs
All drugs other than SL327 were purchased from Tocris
(Bristol, UK) and injected i.p. in a volume of 10 ml/kg, for
biochemical studies, or 4 ml/kg, for behavioural and electrophys-
iological studies. For biochemical studies, SKF 81297 and SCH
23390 were dissolved in 0.9% (w/v) saline. For electrophysiolog-
ical studies SKF 81297 was dissolved in 0.5% DMSO and SCH
23390 in PCR-grade water. CP 55,940 and SL327 (a-[amino[(4-
aminophenyl)-thio]-methylene]-2-(trifluoromethyl)-benzeneaceto-
nitrile; an inhibitor of the mitogen-activated protein kinase/ERK
kinase (MEK), which blocks the phosphorylation/activation of
ERK), a gift from Dr. Edilio Borroni (Hoffmann-La Roche, Basel,
Switzerland), were suspended by sonication in a solution of 8%
Tween 80 in saline and administered i.p. 15 and 60 min before
SKF 81297 injection, respectively. Control animals received
equivalent volumes of the respective vehicles.
Behavioural assessment
For evaluation of drug-induced seizures, mice were removed
from their home cage and placed individually in clear glass
observation cages (38638625 cm) with wood shavings as bedding
material. Mice were then allowed to habituate for a period of 3 h
to reduce initially high levels of activity in order to optimize
detection of agonist-induced behavioural effects. Immediately
following challenge with SKF 81297 (0.5–5.0 mg/kg) or vehicle,
mice were recorded using digital video for 60 min. Video
recordings was subsequently scored for seizures, characterized as
any of the following phases occurring within the 60 min recording
period: phase 1= transient ($5 sec) disruption of exploratory
behaviour by tonic immobility/rigidity; phase 2= rearing with
forepaw myoclonus; phase 3= generalized clonus; phase 4= tonic-
clonic seizure or rapid jumping and wild running (O’Sullivan et al.
2008); all recordings were scored by an observer who was unaware
of the treatment of each animal. The D1R-type antagonist SCH
23390 (0.15 mg/kg) or the cannabinoid CB1 agonist CP 55,940
(0.25 mg/kg) were administered 5 and 15 min, respectively, prior
to administration of SKF 81297. Mice were used once only.
Electroencephalographic recording
Seizure studies were carried out in a manner similar to that
described previously [9]. Briefly, for surgical implantation of
extradural and intrahippocampal recording electrodes, mice
were initially anaesthetised using 5% isoflurane (Abbott Labo-
ratories, Kent, UK) in O2, placed in a stereotaxic frame and
maintained under anaesthesia using 1.5% isoflurane in O2.
Temperature was maintained normothermic (3760.5uC) by
means of a rectal thermometer and thermostatically controlled
heating pad (Harvard Apparatus, MA, USA). The scalp was
incised and a burr hole drilled in the exposed cranium over the
hippocampus and the frontal cortex. A recording electrode and a
frontal reference electrode (Plastics One Inc., VA, USA) were
then implanted. A third complete craniotomy was drilled for the
placement of a twisted bipolar electrode (Plastics One Inc., VA,
USA) into the right dentate gyrus (coordinates from Bregma:
Figure 1. SKF 81297 induces behavioural seizures. Counts for
seizure behaviours (any of phase 1–4 seizure phenotypes; see Materials
and Methods) in mice treated with vehicle, SKF 81297 (0.5–5.0 mg/kg,
i.p.) or SKF 81297 (5.0 mg/kg, i.p.) following administration of SCH
23390 (0.15 mg/kg, i.p.) or CP 55,940 (0.25 mg/kg, i.p.). Data (means 6
SEM; n = 8 mice per group) were analysed using Kruskal-Wallis
nonparametric ANOVA: dose-response for induction of seizures by
SKF 81297 (p,0.05); Mann-Whitney U-tests: * p,0.05 vehicle vs. SKF
81297; u p,0.05 SKF 81297 vs. SKF 81297 following pre-treatment with
SCH 23390 and SKF 81297 following pre-treatment with CP 55,940.
doi:10.1371/journal.pone.0019415.g001
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AP=22.0 mm, L= +0.5 mm, DV=21.5 mm). All electrodes
were affixed to the skull using dental cement (Kemdent,
Wiltshire, UK). Following surgery, animals were placed in an
incubator (Harvard Apparatus, MA, USA) to recover from
anaesthesia before being returned to their home cage. Twenty-
four hr post-surgery, experimental animals were connected to a
digital EEG monitoring apparatus (AS40 amplifier system; Grass
Technologies, RI, USA) and a 30 min baseline cortical/
intrahippocampal EEG was recorded before administration of
SKF 81297 (5.0 mg/kg) or vehicle. A subgroup of animals were
pretreated with CP 55,940 (0.25 mg/kg) or vehicle, 30 min prior
to SKF 81297. EEGs were recorded for 1 hr post-injection and
subsequently analysed by a trained observer unaware of
genotype or treatment for each animal. Electrographic seizures
were defined as high frequency, high amplitude spiking (.1 Hz,
more than twice baseline amplitude) with corresponding
behavioural seizure activity.
Tissue preparation and immunofluorescence
Procedures were as described previously [11,12]. In brief, mice
were rapidly anaesthetized by i.p. injection of pentobarbital
(500 mg/kg, Sanofi-Aventis, France) prior to intracardiac perfu-
sion of 4% (w/v) paraformaldehyde (PFA) in 0.1 M Na2HPO4/
NaH2PO4 buffer, pH 7.5, delivered with a peristaltic pump at
20 ml/min over 5 min. Brains were post-fixed overnight in the
same solution and stored at 4uC. Thirty mm-thick sections were cut
with a vibratome (Leica, France) and stored at220uC in a solution
containing 30% (v/v) ethylene glycol, 30% (v/v) glycerol and
0.1 M sodium phosphate buffer, until they were processed for
immunofluorescence. After permeabilization, free-floating sections
were incubated with rabbit polyclonal antibodies for diphospho-
ERK (phospho-Thr202/Tyr204-ERK1/2, 1:500; Cell Signaling
Technology, Beverly, MA, USA), phospho-Ser10-acetyl-Lys14-H3
(1:500, Millipore, Stockholm, Sweden), phospho-Ser235/236-
ribosomal protein S6 (rpS6; 1:500, Cell Signaling Technology,
Figure 2. SKF 81297 induces electrophysiological seizures. (A) Representative trace showing hippocampal electrographic seizure events
during 60 min following administration of SKF 81297 (5.0 mg/kg, i.p.). Lower panel shows in detail the first and fourth electrographic events. (B)
Quantification of seizure incidence and mean seizure duration determined over a 60 min period of observation. Mean 6 SEM (n= 5 animals). Seizure
incidence and duration peaked between 30–45 min. Electrographic events between 0–15 min and 45–60 min were observed in only one animal each
(data not shown). (C) Representative hippocampal traces over 60 min recording period showing seizures following SKF 81297 administration.
Pretreatment with CP 55,940 (0.25 mg/kg, i.p.) abolishes all SKF 81297-induced seizures.
doi:10.1371/journal.pone.0019415.g002
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Beverly, MA, USA) and mouse monoclonal antibody for MAP2
(1:1000, Sigma-Aldrich, Sweden) overnight at 4uC. Antibodies for
c-Fos (1:400), Arc/Arg3.1 (1:400), and Zif268 (1:400) were
purchased from Santa Cruz biotechnology and were incubated
with tissue sections for 72 h at 4uC in a solution of BSA 1%. After
three rinses in TBS, sections were incubated for 45 min at room
temperature (RT) with goat-anti rabbit Cy3-coupled (1:500) and
goat-anti mouse Cy2-coupled (1:500) secondary antibodies
(Jackson ImmunoResearch Europe Ltd). A monoclonal antibody
against VAMP2 directly coupled to Alexa 488 was used (1:2000;
gift from Dr. Peter Lo¨w, Karolinska Institutet) [13]. Sections were
then rinsed twice in TBS and twice in TB and mounted on a slide
under cover slips using 1,4-diazabicyclo-[2. 2. 2]-octane (DABCO,
Sigma-Aldrich Sweden AB, Stockholm). Fluoro-JadeH (Millipore
Corp., Billica, MA, USA) staining was used to label degenerating
neurons, as previously described [14].
Analysis of immunofluorescence
Bilateral images were obtained using sequential laser scanning
confocal microscopy (Zeiss LSM 510, Jena, Germany) and
quantified using ImageJ software (National Institutes of Health).
Quantification was performed in 325.75 mm6325.75 mm images
by counting Cy2- and Cy3-immunofluorescent cells.
Statistical analysis
Behavioural seizure events were summed over the 60 min
recording period, expressed as means 6 SEM and analysed using
the Kruskal-Wallis non-parametric ANOVA, followed by Mann-
Whitney U-test. Immunofluorescence data were expressed as
means 6 SEM and analyzed by one-way or two-way ANOVA
followed by Bonferonni-Dunn test. Statistical analysis was
performed using StatView software, with p,0.05 adopted as the
threshold for significance.
Results
Seizure profile in response to systemic administration of
SKF 81297
SKF 81297 (0.5–5.0 mg/kg) dose-dependently induced behav-
ioural seizures (p,0.05; Fig. 1), which were observed in 6 (75%) of
8 mice receiving 5.0 mg/kg. Among the 4 phases of seizure
activity recorded (see materials and methods), there was no
significant preponderance of any seizure phenotype. Behavioural
seizures induced by 5.0 mg/kg SKF 81297 were abolished by
pretreatment with either 0.15 mg/kg SCH 23390 or 0.25 mg/kg
CP 55,940 (each p,0.05; Fig. 1).
Simultaneous EEG recordings from skull-mounted surface
electrodes and intra-cerebral depth recordings from the DG
following injection of SKF 81297 (5.0 mg/kg) demonstrated the
presence of seizures (high amplitude and high frequency
discharges) in the DG in 5 (71%) of 7 mice; mean latency to
emergence of seizures was 2262 min. There was a time-
dependent increase in seizure incidence and duration following
injection of SKF 81297 (Fig. 2), with seizure severity peaking at
30–45 min post-injection and declining by 60 min (Fig. 2B, C). No
seizure activity was evident in vehicle-treated mice (n = 5; data not
shown).
The SKF 81297-induced seizures were not accompanied by the
appearance of neurodegenerative responses, as determined by
Fluoro-Jade staining, 6 hrs after recording (data not shown).
SKF 81297-induced seizures are associated with an
increase of ERK phosphorylation selectively in the
dentate gyrus of the hippocampus
Pharmacological induction of seizures by KA and pilocarpine is
accompanied by increased ERK phosphorylation in several
hippocampal regions [15,16,17]. Therefore we examined the
induction and distribution of phospho-ERK (P-ERK) in the
hippocampus of mice treated with SKF 81297. Administration of
2.5 and 5.0 mg/kg SKF 81297 resulted in a large increase in P-
ERK immunoreactivity selectively in the granule cell layer of the
DG (Fig. 3A, B and D). This effect peaked at 15–30 min post-
injection and declined by 60 min (Fig. 3C and E). P-ERK
immunoreactivity was detected in neuronal nuclei and perikarya,
as well as in the dendrites of almost all the granule cells of the DG
(Fig. 3A–C). In contrast, administration of 5.0 mg/kg SKF 81297
did not affect ERK phosphorylation in the CA3 and CA1
pyramidal neurons (Fig. 3F and G). Dendritic activation of ERK
was confirmed by the strong co-localization of P-ERK with the
microtubule-associated protein 2 (MAP2), a protein highly
enriched in dendrites (Fig. 4A). In contrast, no co-localization of
P-ERK immunoreactivity was found with a marker of nerve
terminals, the vesicle-associated membrane protein 2 (synapto-
brevin 2, also known as VAMP2) (Fig. 4B). The effect of SKF
81297 (5 mg/kg) on ERK phosphorylation was compared to those
produced by the D1-type agonists SKF 83822 and SKF 83959,
which are considered to preferentially activate cAMP and
phospholipase C signaling, respectively [9]. We found that SKF
83822 (2 mg/kg) produced an increase in the number of P-ERK
positive neurons comparable to that of SKF 81297 (Figure S1).
The same dose of SKF 83959 was also able to increase ERK
phosphorylation, however its effect was significantly lower than
those produced by SKF 81297 or SKF 83822 and appeared to be
preferentially exerted in the cytoplasm (Figure S1).
SKF 81297-induced ERK phosphorylation is prevented by
inactivation of dopamine D1 receptors
The increase in ERK phosphorylation produced by 2.5 or 5.0 mg/
kg SKF 81297 was abolished by 0.15 mg/kg SCH 23390 (Fig. 5A
and B) and was absent in mice with deletion of D1Rs (Fig. 5C and D).
These results indicate that SKF 81297-induced seizures increase ERK
phosphorylation in the DG through stimulation of D1Rs.
SKF 81297 induces phospho-acetylation of histone H3
and phosphorylation of rpS6
We proceeded by determining whether SKF 81297-induced
seizures enhanced phosphorylation of histone H3, an important
downstream nuclear target of ERK involved in the nucleosomal
Figure 3. SKF 81297 induces ERK phosphorylation in the dentate gyrus. (A) Single confocal section showing phosphorylated ERK (P-ERK) in
the hippocampus of mice treated with vehicle or SKF 81297 (5.0 mg/kg, i.p.). Scale bar: 150 mm. (B) Dose-response (0, 0.5, 1, 2.5, and 5.0 mg/kg) and
(C) time course (0, 15, 30, 60 and 180 min) of P-ERK in mice treated with SKF 81297. Scale bar: 40 mm. (D and E) Quantification of phosphorylated ERK
(P-ERK) immunoreactive neurons in the dentate gyrus of mice treated with vehicle or SKF 81297. Data (means 6 SEM; n= 3–4 mice per group) were
analyzed using one-way ANOVA: dose-response (F(4,9) = 61.22; p,0.001), time course (F(5,12) = 239.78; p,0.001). (F) Single confocal section showing P-
ERK in the CA3 and CA1 areas of mice treated with vehicle or SKF 81297 (5.0 mg/kg, i.p.). Scale bar: 40 mm. (G) Quantification of P-ERK
immunoreactive neurons in CA3 and CA1 of mice treated with vehicle or SKF 81297. Data (means 6 SEM; n = 4–5 mice per group) were analyzed
using student t-test: CA3 (F(1,7) = 1.23; NS), CA1 (F(1,7) = 0.65; NS).
doi:10.1371/journal.pone.0019415.g003
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response [18]. Mice given 5.0 mg/kg SKF 81297 showed a robust
increase in the number of phospho-acetyl-H3 (P-AcH3) immuno-
reactive neurons, restricted to the granule cell layer of the DG
(Fig. 6A, upper panels and B); P-AcH3 was maximal 30 min after
SKF 81297 administration and returned to basal levels within 3 hr
(Fig. 6A and B). This effect of SKF 81297 was abolished by
0.15 mg/kg SCH 23390 (Fig. 6D) and by deletion of D1Rs (Fig. 6F).
We next examined the state of phosphorylation of rpS6, a
component of the 40S ribosomal subunit [19] which can be
phosphorylated by ERK via the 90 kDa ribosomal S6 kinases (RSK)
Figure 4. SKF 81297-induced ERK phosphorylation occurs at the postsynaptic level. (A and B) Single confocal sections showing P-ERK)
(red) and MAP2 (green, upper panel) or VAMP2 (green, lower panel) immunofluorescence in the dentate gyrus of mice 15 min after SKF 81297
(5.0 mg/kg, i.p.). Note that P-ERK immunoreactive neurons are observed in MAP2-positive cells, suggesting that ERK activation induced by SKF 81297
occurred mainly at the postsynaptic level. Scale bar: 20 mm.
doi:10.1371/journal.pone.0019415.g004
Figure 5. D1Rs are required for SKF 81297-induced ERK phosphorylation in the dentate gyrus. (A) Immunohistochemical detection of P-
ERK in the granule cell layer of mice treated with vehicle, SKF 81297 (SKF; 5.0 mg/kg, i.p.) alone or in combination with SCH 23390 (0.15 mg/kg, i.p.).
Scale bar: 40 mm. (B) Quantification of P-ERK immunoreactive neurons in the dentate gyrus of mice treated with vehicle and SKF 81297 alone or in
combination with SCH 23390 (0.15 mg/kg, i.p.). Data (means 6 SEM; n = 2–4 mice per group) were analyzed using two-way ANOVA: effect of SKF
81297 (F(2,11) = 77.09; p,0.001), SCH 23390 (F(1,11) = 347.53; p,0.001), interaction (F(2,11) = 77.97; p,0.01). (C) Immunohistochemical detection of P-
ERK in the granule cell layer of wildtype or D1R knock out (D1R KO) mice treated with vehicle or SKF 81297. Scale bar: 40 mm. (D) Quantification of P-
ERK immunoreactive neurons in the dentate gyrus of wildtype or D1R knock out (D1R KO) mice treated with vehicle or SKF 81297. Data (means 6
SEM; n = 2–3 mice per group) were analyzed using two-way ANOVA: effect of genotype (F(1,6) = 48.21; p,0.001), treatment (F(1,6) = 44.11; p,0.001,
interaction (F(1,6) = 40.19; p,0.001). Bonferroni-Dunn test: ** p,0.01, *** p,0.001 vehicle vs. SKF 81297; uuu p,0.001 vehicle vs. SCH 23390 and
wildtype vs. D1R KO.
doi:10.1371/journal.pone.0019415.g005
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at the dual site Ser235/236 [20]. Mice given 5.0 mg/kg SKF 81297
showed a rapid, transient increase in the number of phospho-S6
immunoreactive neurons selectively in the granule cells of the DG
(Fig. 6A, lower panel and C). This effect of SKF 81297 was abolished
by 0.15 mg/kg SCH23390 (Fig. 6E) and by deletion ofD1Rs (Fig. 6G).
Activation of CB1 receptors abolishes SKF 81297-induced
seizures and reduces phosphorylation of ERK, AcH3 and
rpS6
Activation of CB1 receptors, which are abundantly expressed in
the hippocampus, has been shown to reduce KA-induced seizures
[5,6]. CP 55,940 (0.25 mg/kg) antagonized SKF 81297 (5.0 mg/
kg)-induced phosphorylation of ERK (Fig. 7A and B), AcH3
(Fig. 7C and D) and rpS6 (Fig. 7E and F) in the granular cells of
the DG. Thus endocannabinoids, through activation of CB1
receptors, appear to exert an anticonvulsant effect against D1R-
induced seizures.
SKF 81297-induced phosphorylation of AcH3 and rpS6
depends on ERK activation
Parallel increases in the state of phosphorylation of ERK,
histone H3 and rpS6 produced by administration of SKF 81297
suggest a causal link between these effects. To examine this
possibility we used SL237, an inhibitor of mitogen-activated
protein kinase/ERK kinase (MEK) which blocks the phosphory-
lation/activation of ERK. The increase in ERK phosphorylation
induced by 5.0 mg/kg SKF 81297 was antagonized by a 60 min
pretreatment with 50 mg/kg SL327 (Fig. 8A and B). The blockade
of ERK phosphorylation was accompanied by antagonism of
phosphorylation of AcH3 (Fig. 8C and D) and P-rpS6 (Fig. 8E and
F).
SKF 81297 promotes the expression of Arc/Arg3.1 and
Zif268 via activation of ERK
We next investigated whether systemic activation of D1Rs is
accompanied by induction of immediate early genes (IEGs) in the
hippocampus by determining the effect of 5.0 mg/kg SKF 81297
on levels of Arc/Arg3.1, Zif268 and c-Fos. SKF 81297 induced a
large increase in expression of Zif268 and Arc/Arg3.1, specifically
in the granule cell layer of the DG (Fig. 9A); Zif268 expression
increased at 30 min, peaked at 60 min and returned to basal levels
360 min after SKF 81297 administration (Fig. 9B). The increase in
Arc/Arg3.1 expression was more transient; Arc/Arg3.1 expression
was first observed at 60 min and returned to basal level 180 min
after SKF 81297 administration (Fig. 9C). Increases in Arc/Arg3.1
and Zif268 expression induced by SKF 81297 (5.0 mg/kg) were
abolished by pre-treatment with 50 mg/kg SL327 (Fig. 9D, E and
F). In contrast, SKF 81297 administration induced only a very
modest increase in c-Fos expression in dentate gyrus which did not
reach statistical significance when using the Bonferroni post-hoc
test (Figure S2).
Discussion
This study describes a series of unique molecular changes
occurring in the hippocampal formation in association with the
emergence of epileptiform activity induced by activation of D1Rs.
These changes are distinct from those produced by acute injection
of chemoconvulsants, such as pilocarpine or KA, and involve
increased activation of ERK specifically in the cytoplasm and
nuclei of granule cells, leading to phosphorylation of histone H3
and rpS6, and enhanced expression of Zif268 and Arc/Arg3.1.
It has been shown that D1R agonists synergise with subthresh-
old doses of pilocarpine to induce SE [7]. In addition, it has been
reported that, in the mouse, administration of the D1-type
receptor agonist SKF 83822 generates seizures [8,9]. This pro-
convulsant effect requires intact D1Rs, but not D5Rs, and involves
activation of cAMP signaling. In addition, western blot analysis
revealed that SKF 83822-induced epileptiform activity was
paralleled by a large increase in phospho-ERK immunoreactivity
in the hippocampus [9].
Increased ERK phosphorylation in the hippocampal formation
is a common response induced by chemoconvulsants. Adminis-
tration of pilocarpine at doses able to induce SE and spontaneous
seizures increases ERK phosphorylation in the DG, including the
hilar region, and, to a lesser extent, in the CA1 [16,21]. In this
study, we show that administration of the D1-type receptor agonist
SKF 81297 is also able to enhance phospho-ERK immunoreac-
tivity in the DG. However, we do not observe any increase in
ERK phosphorylation in the CA3 and CA1 pyramidal neurons.
Moreover, SKF 81297 does not increase ERK phosphorylation in
the interneurons of the hilar region that are affected by
administration of pilocarpine and KA [16,22]. Thus, it appears
that the degree of activation produced by SKF 81297 in the DG is
lower than that necessary to model temporal lobe epilepsy. This is
in line with the inability of SKF 81297 to generate SE, neuronal
damage or later spontaneous seizures.
The increase in ERK phosphorylation produced by SKF 81297
is abolished by genetic inactivation of D1Rs, which also prevents
the ability of another D1-type receptor agonist, SKF 83822, to
induce epileptiform activity [8,9]. The existence of a link between
D1R-mediated induction of seizures and ERK signaling is further
suggested by the observation that administration of the D1-type
receptor antagonist SCH 23390, or the cannabinoid CB1 agonist
CP 55,940, which prevent the manifestation of epileptiform
activity, also prevent the ability of SKF 81297 to activate ERK.
The increase in ERK phosphorylation produced in the DG by
administration of SKF 81297 is short-lived and disappears within
60 min after drug administration. This contrasts with the effects of
pilocarpine and KA, whose administration leads to increases in
Figure 6. SKF 81297 induces histone H3 phospho-acetylation and rpS6 phosphorylation in the dentate gyrus. (A) Single confocal
sections showing immunofluorescence detection of phospho-Ser10-acetyl-Lys14 histone H3 (P-AcH3, upper panel) and phospho-rpS6 (P-rpS6, lower
panel) in mice treated with vehicle or SKF 81297 (5.0 mg/kg, i.p.). Scale bar: 40 mm. (B and C) Quantification of P-AcH3 and P-rpS6 immunoreactive
neurons in time course study performed in mice treated with vehicle or SKF 81297 (5.0 mg/kg, i.p.). Data (means 6 SEM; n = 3 mice per group) were
analyzed using one-way ANOVA: P-AcH3 (F(5,12) = 148.78; p,0.001); P-rpS6 (F(5,20) = 33.45; p,0.001). (D and E) Quantification of P-AcH3 and P-rpS6
immunoreactive neurons after pharmacological antagonism with the D1-like family antagonist SCH 23390 (0.15 mg/kg, i.p.). Data (means 6 SEM;
n = 4 mice per group) were analyzed using two-way ANOVA: P-AcH3, effect of SKF 81297 (F(1,9) = 67.38; p,0.001), SCH 23390 (F(1,9) = 55.25; p,0.001),
interaction (F(1,9) = 57.04; p,0.001); P-rpS6, effect of SKF 81297 (F(1,7) = 352.36; p,0.001), SCH 23390 (F(1,7) = 383.77; p,0.001), interaction
(F(1,7) = 402.32; p,0.001). (F and G) Quantification of P-AcH3 and P-rpS6 immunoreactive neurons in wildtype and D1R knock out (D1R KO) mice
treated with vehicle or SKF 81297 (5.0 mg/kg, i.p.). Data (means6 SEM; n = 2–4 mice per group) were analyzed using two-way ANOVA: P-AcH3, effect
of genotype (F(1,8) = 56.01; p,0.001), treatment (F(1,8) = 59.37; p,0.001), interaction (F(1,8) = 58.24; p,0.001); P-rpS6, effect of genotype (F(1,6) = 360.91;
p,0.001), treatment (F(1,6) = 313.63; p,0.001), interaction (F(1,6) = 321.28; p,0.001). Bonferroni-Dunn test: *** p,0.001 vehicle vs. SKF 81297,
uuu p,0.001 vehicle vs. SCH 23390 or wildtype vs. D1R KO.
doi:10.1371/journal.pone.0019415.g006
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ERK phosphorylation that last for hours [16,17,21]. Overall, the
transient activation of ERK induced by SKF 81297 corresponds to
the number and duration of seizure events, which peak at 30 min
following SKF 81297 administration and decline by 60 min. A
more precise analysis of the time at which the first seizures are
generated suggests that maximal ERK phosphorylation, which
occurs within 15 min after drug administration, may precede the
onset of epileptiform activity, which occurs at 20–25 min after
drug administration. However that ERK plays a role in the
generation of seizures is challenged by the observation that
administration of SL327, which abolishes ERK phosphorylation,
does not affect pilocarpine-induced seizures [21]. Therefore,
increased ERK signaling in the DG most likely represents a
marker of neuronal activation indicative of D1R agonist-induced
seizures, rather than the cause of such seizures. Interestingly,
recent work in a mouse model of pilocarpine-induced temporal
lobe epilepsy proposes that phosphorylated ERK may represent an
early indicator of activated neurons during spontaneous seizures
[23]. Furthermore, the spatio-temporal patterns of ERK phos-
phorylation associated with D1R-mediated seizures and sponta-
neous (i.e. epileptic) seizures are very similar, suggesting that these
two phenomena may recruit the same hippocampal circuits.
Figure 7. Effect of CB1 receptor activation on ERK, AcH3 and rpS6 phosphorylation. Immunohistochemical detection of P-ERK (A), P-AcH3
(C) and P-rpS6 (E) in the granule cell layer of mice treated with vehicle, SKF 81297 (SKF; 5.0 mg/kg) alone or in combination with the CB1 receptor
agonist, CP 55,940 (0.25 mg/kg, i.p.). Scale bar: 40 mm. (B, D and F) Quantification of P-ERK, P-AcH3 and P-rpS6 immunoreactivity in mice treated with
vehicle, SKF alone or in combination with CP 55,940. Data (means 6 SEM; n= 2–4 mice per group) were analyzed using one-way ANOVA: P-ERK
(F(2,5) = 149.01, p,0.001); P-AcH3 (F(2,6) = 13.79, p,0.01); P-rpS6 (F(2,9) = 30.08, p,0.001). Bonferroni-Dunn test: ** p,0.01, *** p,0.001 vehicle vs. SKF,
uu p,0.01, uuu p,0.001 vs. SKF.
doi:10.1371/journal.pone.0019415.g007
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The activation of ERK produced by administration of SKF
81297 occurs both in the cytoplasm and in the nucleus of granule
cells, as shown by the presence of phosphorylated ERK in these
two compartments. In line with this observation, we found that
activation of D1Rs increased the state of phosphorylation of rpS6
and histone H3, two downstream targets of ERK selectively
expressed in the cytoplasm and the nucleus, respectively. Time-
course analysis indicated a rapid increase in rpS6 phosphorylation,
which peaked at 15 min after administration of SKF 81297, and a
more progressive increase in histone H3 phosphorylation, which
reached a peak at 30 min and was still significantly elevated at
60 min. Such kinetics of phosphorylation indicates a rapid and
more transient activation of ERK signaling in the cytoplasm,
paralleled by a slower and more resilient activation in the nucleus.
Phosphorylation of rpS6 is likely to occur via activation of RSK,
a direct ERK substrate and major rpS6 kinase, phosphorylation of
which was also enhanced following SKF 81297 administration
(data not shown). However, the increase in rpS6 phosphorylation
Figure 8. AcH3 and rpS6 phosphorylation induced by SKF 81297 is dependent on ERK activation. Immunohistochemical detection of P-
ERK (A), P-AcH3 (C) and P-rpS6 (E) in the granule cell layer of mice treated with vehicle, SKF 81297 (5.0 mg/kg, i.p.) alone or in combination with the
MEK inhibitor, SL327 (50 mg/kg, i.p.). Scale bar: 40 mm. (B, D and F) Quantification of P-ERK, P-AcH3 and P-rpS6 immunoreactive neurons in mice
treated with SKF 81297 alone or in combination with SL327 (50 mg/kg, i.p.) and perfused 15 and 30 min later. Data (means 6 SEM; n = 4–5 mice per
group) were analyzed using two-way ANOVA: P-ERK, effect of time (F(1,10) = 0.61, NS), treatment (F(1,10) = 235.19, p,0.001), interaction (F(1,10) = 2.91,
NS); P-AcH3, effect of time (F(1,10) = 8.05, p,0.02), treatment (F(1,10) = 91.73, p,0.001), interaction F(1,10) = 4.27, NS); P-rpS6, effect of time (F(1,17) = 34.54,
p,0.001), treatment (F(1,17) = 17.67, p,0.001), interaction (F(1,17) = 0.16, NS). Bonferroni-Dunn test: ** p,0.01, *** p,0.001 vehicle vs. SL327.
doi:10.1371/journal.pone.0019415.g008
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produced by SKF 81297 was only partially reduced by SL327, a
drug, which prevents the phosphorylation of ERK, indicating the
involvement of other signaling cascades in D1R-mediated control
of this particular downstream target. In contrast, SKF 81297-
induced phosphorylation of histone H3 at Ser10 was abolished by
pretreatment with SL327. Surprisingly, ERK activation was not
accompanied by increased phosphorylation of MSK1 or MSK2
(data not shown), two major substrates of ERK critically involved
in histone H3 phosphorylation [24,25,26]. Therefore, the
molecular link between ERK activation and histone H3
phosphorylation remains to be identified.
Induction of gene expression has been extensively studied in
various experimental models of seizures. For instance, increased
expression of genes coding for activity-regulated transcription
factors, such as c-fos and zif268, has been demonstrated in the
hippocampus after kindling [27,28], or following electrical or
chemical induction of seizures [29,30,31,32,33,34]. Moreover a
strong induction of c-Fos has been observed in the granule neurons
of the DG following a spontaneous seizure [23].
In the present study, we found a large increase in levels of
Zif268 in the nuclei of granule cells, which followed temporally the
increase in ERK and histone H3 phosphorylation produced by
SKF 81297. This effect was prevented by treatment with SL327,
indicating that phosphorylation of ERK and, possibly, of histone
H3 is implicated in the expression of this gene. However, previous
studies showed that inhibition of MSK1, which prevents cocaine-
induced phosphorylation of histone H3 at Ser10, did not prevent
the ability of this drug to increase the expression of zif268 [24].
Thus, further studies will be necessary in order to demonstrate the
involvement of histone H3 phosphorylation in the regulation of
zif268 expression, in the dentate gyrus.
In contrast to Zif268, we found only a small increase in c-Fos
expression following D1R activation in the dentate gyrus. The
pattern of immediate early gene induction observed with SKF
81297 is similar to that described following high frequency
stimulation of the perforant pathway, which induces LTP in the
DG. Thus, tetanising stimuli increase Zif268, without consistently
affecting c-Fos expression [35,36,37,38]. Moreover, the increase in
Zif268 expression associated with LTP is prevented by inhibition
of ERK with SL327 [39].
Administration of SKF 81297 increases also the levels of Arc/
Arg3.1, another gene involved in multiple forms of neuronal
plasticity, including LTP and LTD. Previous work proposed that
the involvement of Zif-268 in the late phase of LTP is related to its
ability to promote Arc/Arg3.1 transcription [40]. Levels of Arc/
Arg3.1 are also regulated at the translational level, following rapid
transport of mRNA to dendrites [41]. Thus, the increased
expression of Arc/Arg3.1 induced by activation of D1Rs may
depend on concomitant ERK-dependent phosphorylation of
histone H3, which may be implicated in the nucleosomal response,
and rpS6, which may instead regulate local synaptic translation of
mRNA encoded by Arc/Arg3.1. In support of this possibility, it has
recently been shown that, in the hippocampus, activation of ERK
promotes local Arc/Arg3.1 expression independently of other
signaling pathways involved in translational control, such as the
mammalian target of the rapamycin cascade [42].
Changes in the expression of zif268 and Arc/Arg3.1 reported
here have been studied with respect to their involvement in
hippocampal plasticity. Dopamine transmission has been impli-
cated in various forms of learning and memory, in which the
hippocampal formation is though to play an essential role. In
many cases, the action of dopamine has been proposed to occur
via activation of D1- or D2-type receptors located in various
anatomical regions within the hippocampal formation. It will be
interesting to define whether the effects described here are
produced by a direct action of SKF 81297 on the granule cells
of the DG, or by an indirect mechanism involving a polysynaptic
circuit.
In conclusion, the present study indicates that the epileptiform
activity produced by systemic administration of a D1R agonist is
associated with activation of ERK in the granule cells of the DG.
This effect is accompanied, in the nucleus, by increased
phosphorylation of histone H3 and expression of zif268.
Moreover, administration of SKF 81297 enhances phosphoryla-
tion of rpS6 in the cytoplasm and promotes the expression of Arc/
Arg3.1. These changes are distinct from those produced by
chemoconvulsants, such as pilocarpine and KA, which cause a
much more pervasive and prolonged activation of the DG and
other hippocampal regions and which trigger the expression of
additional immediate early genes. The more restricted action of
SKF 81297 is consistent with the inability of this drug to induce
SE, spontaneous seizures and neuronal cell death, and further
supports the notion that the DG acts as a gate and sensor able to
detect a wide range of stimuli impinging on the hippocampus.
Future studies will be required to elucidate the significance of
D1R-mediated molecular changes in hippocampal plasticity and
function.
Supporting Information
Figure S1 Effect of SKF 81297 on c-Fos expression in the
dentate gyrus. (A) Single confocal sections showing immuno-
fluorescence detection of c-Fos protein expression at various times
after SKF 81297 (5.0 mg/kg, i.p.) injection. Scale bar: 40 mm. (B)
Quantification of c-Fos immunoreactive neurons in mice treated
with vehicle or SKF 81297 (5.0 mg/kg, i.p.) at various time points.
Data (means 6 SEM; n= 3–6 mice per group) were analyzed
using one-way ANOVA: c-Fos (F(5,12) = 6.14; p,0.05). Bonferroni-
Dunn test: NS.
(TIF)
Figure S2 SKF 81297, SKF 83822 and SKF 83959 induce
ERK phosphorylation in the dentate gyrus. (A) Single
confocal section showing P-ERK in the DG following systemic
administration of SKF 81297 (5.0 mg/kg, i.p.), SKF 83822
(2.0 mg/kg, i.p.) and SKF 83959 (2.0 mg/kg, i.p.). Scale bar:
40 mm. (B) Quantification of P-ERK immunoreactive neurons
Figure 9. Zif268 and Arc/Arg3.1 expression induced by SKF 81297 is dependent on ERK activation. (A) Single confocal sections showing
immunofluorescence detection of Zif268 and Arc/Arg3.1 protein expression at various times after SKF 81297 (5.0 mg/kg, i.p.) injection. Scale bar:
40 mm. (B and C) Quantification of Zif268 and Arc/Arg3.1 immunoreactive neurons in mice treated with vehicle or SKF 81297 (5.0 mg/kg, i.p.) at
various time points. Data (means 6 SEM; n= 3–6 mice per group) were analyzed using one-way ANOVA: Zif268 (F(5,12) = 36.50; p,0.001), Arc/Arg3.1
(F(5,21) = 23.50; p,0.001). (D) Immunohistochemical detection of Zif268 and Arc/Arg3.1 and protein expression in the granule cell layer of mice treated
with SKF 81297 (5.0 mg/kg) alone or in combination with SL327 (50 mg/kg, i.p.). Scale bar: 40 mm. (E and F) Quantification of Zif268 and Arc/Arg3.1
immunoreactive neurons in mice treated with SKF 81297 (5.0 mg/kg) alone or in combination with SL327 (50 mg/kg, i.p.) at two time points. Data
(means 6 SEM; n = 3–4 mice per group) were analyzed using two-way ANOVA: Zif268, effect of time (F(1,10) = 105.87, p,0.001), SL327 (F(1,10) = 239.57,
p,0.001), interaction (F(1,10) = 42.45, p,0.001); Arc/Arg3.1, effect of time (F(1,12) = 123.88, p,0.001), SL327 (F(1,12) = 143.47, p,0.001), interaction
(F(1,12) = 70.12, p,0.001). Bonferroni-Dunn test: *** p,0.001 vehicle vs. SL327.
doi:10.1371/journal.pone.0019415.g009
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after pharmacological treatment with the D1-type receptor
agonists. Data (means 6 SEM; n= 3–4 mice per group) were
analyzed using one-way ANOVA: treatment (F(3,10) = 236.16;
p,0.001). Bonferroni-Dunn test: *** p,0.001 and uuu p,0.001.
(TIF)
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